Day: April 19, 2022

Full Year 2021 Corporate Update: Sono Motors Solar Technology Delivered to Several Partners and Sion Production Capacity Secured

Written by Customer Service on April 19, 2022. Posted in Earnings Releases And Operating Results.

Sono Motors Sion Sono Motors SionSono Motors B2B Solar Range Sono Motors B2B Solar RangeSeveral B2B Projects for Solar Integration Delivered, Including Solar Buses for Public Transport in Q1 2022, Last Mile Delivery Truck and US RV Retailer in 2021. Between 2021 and Q1 2022 Sono Solar B2B Partner Arrangements Increased From 2 to 17. Signed a Contract Manufacturer With Years of Experience in Production for Premium OEMs, Which Will Provide Production Capacity for 257,000 Cars Within 7 Years. As of 31 March 2022, Reservations for The Sion Solar Electric Vehicle (SEV) Totaled Over 17,000, With an Average Down Payment of €2,390 Net. Development of the Sion Progressed as Planned With Building of a Series-Validation Vehicle Fleet, to Be Presented to the Public This Summer. Sono Car Sharing App Launched in Germany.MUNICH, Germany, April...

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Written by Customer Service on April 19, 2022. Posted in Mergers And Acquisitions.

Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an...

Quipt Accelerates National Expansion Efforts with Acquisition of Multi State Operator – Good Night Medical – Significantly Bolstering Commercial Contract Portfolio

Written by Customer Service on April 19, 2022. Posted in Mergers And Acquisitions.

Acquisition Adds $7.5 Million in Annualized Revenues, 20% Adjusted EBITDA Margin Post Integration, and Over 10,000 Active Patients CINCINNATI, April 19, 2022 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce that it has acquired Good Night Medical, LLC (“Good Night Medical”), a business with operations across seven U.S. states, reporting unaudited trailing 12-month annual revenues of approximately $7.5 million ‎and with anticipated Adjusted EBITDA (defined below) of $1.5 million (20% margin) post integration. As a reminder all figures stated are in USD. Acquisition Details The acquisition encompasses locations across seven U.S. states including Arkansas, Georgia,...

Microbix Presenting Respiratory Virus Controls Data at Two Events

Written by Customer Service on April 19, 2022. Posted in Public Companies.

QAPs Supporting Tests That Simultaneously Detect Multiple Respiratory Viruses MISSISSAUGA, Ontario, April 19, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be presenting performance results of its quality assessment products (“QAPs™”) that support molecular-diagnostic (“MDx”) screening-tests for respiratory viruses at two industry congresses – “Labquality Days” in Helsinki, Finland April 20-21, 2022 and “ECCMID 2022” in Lisbon, Portugal, April 23-26, 2022. Labquality Days is an annual international congress focusing on quality in laboratory medicine and medical devices. It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab proficiency and accreditation authority that is also a Microbix distribution...

Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Med

Written by Customer Service on April 19, 2022. Posted in Public Companies.

EDEN PRAIRIE, Minn., April 19, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mediterranean. The conference, held this year on April 20 – 22 in Barcelona, Spain, brings together the leading public and private sector companies in the field of advanced therapies. Mr. Ross will deliver his remarks at 3:45 pm CET on April 21st live from the Gaudi 3 Ballroom, which will be simultaneously streamed for virtual attendees. The recordings will also be uploaded into the virtual platform within 24 hours for further on-demand viewing. A short Q&A will follow his presentation. “I am honored to have...

LIZHI Collaborates with Xiaomi Quick App Platform to Launch In-car Audio Product in Leapmotor Smart Electric Vehicles

Written by Customer Service on April 19, 2022. Posted in Public Companies.

GUANGZHOU, China, April 19, 2022 (GLOBE NEWSWIRE) — LIZHI INC. (“LIZHI” or the “Company” or “We”) (NASDAQ: LIZI), an audio-based social and entertainment platform, announced that it is collaborating with the in-car Xiaomi Quick App Platform to integrate LIZHI’s in-car audio product into Leapmotor vehicles’ operating system. Leapmotor is a smart electric vehicle (EV) automaker based in China. This partnership marks Leapmotor as the first smart car company to integrate LIZHI’s in-car audio product through the Xiaomi Quick App Platform. With the Company’s experience as a pioneer of building audio content ecosystems and applications for smart vehicles, LIZHI has rapidly adapted its in-car audio products for the Quick App Platform, working with Xiaomi Inc. and Qcarlink Inc. to introduce audio products specifically catered for the platform...

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

Written by Customer Service on April 19, 2022. Posted in Public Companies.

Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development Extends Company’s cash runway into 2025 NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced strategic financing agreements with funds managed by Oaktree Capital Management, L.P. (“Oaktree”) and Qatar Investment Authority (“QIA”). Under the agreements, Oaktree and QIA will provide up to $260 million in gross funding to support the Company’s commercial activities of IGALMI™ (dexmedetomidine) sublingual film. In addition, the financing is intended to support...

CTG Continues to Execute on Strategy to Drive Client Success with Advanced Digital Solutions; Promotes Brett Hunt to Vice President, North America Solutions and Delivery

Written by Customer Service on April 19, 2022. Posted in Public Companies.

BUFFALO, N.Y., April 19, 2022 (GLOBE NEWSWIRE) — CTG (Nasdaq: CTG) (“Company”), a leader in helping companies employ digital IT solutions and services to drive productivity and profitability in North America and Western Europe, announced today the promotion of Brett Hunt to the newly formed position of Vice President of Solutions and Delivery, North America. “As we accelerate the execution of our strategy to strengthen CTG’s digital solutions to help our clients achieve more, we are structuring the organization to facilitate scalability and speed. It takes the right people in the right roles to drive change,” said Filip Gydé, CTG President and CEO. “Brett has proven in the short time he has been with CTG that he has the tenacity and conviction to deliver on our vision. He has captured new business, created new customer and partner...

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

Written by Customer Service on April 19, 2022. Posted in Public Companies.

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (“NDA”) referencing BENDEKA®. The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances. “We are pleased with the outcome of the settlement, as we continue to expand and vigorously defend the intellectual property around BENDEKA and our bendamustine franchise through patent enforcement and litigation,” stated Scott Tarriff, President and Chief Executive Officer. Eagle previously asserted several Orange Book-listed patents...

embecta Announces Second Quarter 2022 Earnings Conference Call Information

Written by Customer Service on April 19, 2022. Posted in Public Companies.

FRANKLIN LAKES, N.J., April 19, 2022 (GLOBE NEWSWIRE) — Embecta Corp. (embecta) (NASDAQ: EMBC) today announced that it will report its financial results for the second quarter of fiscal year 2022 before the market opens on Friday, May 13, 2022. Management will host a conference call at 8:00 a.m. Eastern Time (ET) on May 13 to discuss the results of the quarter, provide an update on its business, including financial guidance for 2022, and host a question and answer session. Those who would like to participate may dial 800-374-1601 (U.S.) or 210-787-4744 (International) and provide access code 5596984. The call can also be accessed through a live webcast on the company’s website at investors.embecta.com. An audio replay of the call will be available beginning at 11:00 a.m. ET on May 13, 2022, either on the embecta website or...

Day: April 19, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice